WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014186469) HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/186469    International Application No.:    PCT/US2014/038005
Publication Date: 20.11.2014 International Filing Date: 14.05.2014
IPC:
C12N 5/0783 (2010.01), C12N 5/10 (2006.01), C12N 15/85 (2006.01), A61K 35/14 (2015.01), A61P 37/00 (2006.01)
Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th St. Austin, TX 78701 (US)
Inventors: COOPER, Laurence, J.N.; (US).
TORIKAI, Horoki; (US).
ZHANG, Ling; (US).
HULS, Helen; (US).
WANG-JOHANNING, Feng; (US).
HURTON, Lenka; (US).
OLIVARES, Simon; (US).
KRISHNAMURTHY, Janani; (US)
Agent: BYRD, Marshall, P.; Parker Highlander PLLC 1120 So. Capital Of Texas Highway Building One, Suite 200 Austin, TX 78746 (US)
Priority Data:
61/823,253 14.05.2013 US
Title (EN) HUMAN APPLICATION OF ENGINEERED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
(FR) APPLICATION À DES HUMAINS DE LYMPHOCYTES T COMPRENANT UN RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE (CAR)
Abstract: front page image
(EN)The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
(FR)La présente invention concerne des procédés et des compositions d'immunothérapie utilisant un lymphocyte T modifié comprenant un récepteur antigénique chimérique (CAR). Dans certains aspects, des lymphocytes T exprimant CAR sont produits à l'aide de l'électroporation en association avec un système d'intégration à base de transposon pour produire une population de cellules exprimant CAR qui nécessitent une expansion ex vivo minimale or qui peuvent être administrées directement à des patients pour le traitement de leur maladie (par ex. le cancer).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)